Clinical Trials Logo

Clinical Trial Summary

The investigators will study, prospectively, if contacts (household or close contacts) of tuberculosis (TB) patients with high C-reactive protein (CRP), low hemoglobin (Hb) levels, and a positive Xpert Host Response (HR) cartridge result develop active TB within 12 months. They will also investigate if there is a correlation between progressing to active TB within 12 months and having high levels of the iron homeostasis markers (Hepcidin, Ferritin and Transferrin). Identified index cases who agree to participate will refer their household or close contacts to also join the study. These contacts will be tested for TB and only contacts who are negative will be enrolled and followed-up at 6 months and 12 months. Blood samples will be collected at baseline and 6 months for testing. During the study period, TB testing will be done on contacts who meet symptoms criteria. At 12 months, all contacts will undergo a chest x-ray to assist in the diagnosis of TB. PreFIT will target people aged 12 to 60 years of age and both HIV negative and positive. 1515 trial participants will be recruited at Stellenbosch University in South Africa, 1515 at Fundaçao Manhiça in Mozambique and 1010 at Makerere University in Uganda, respectively.


Clinical Trial Description

Although the estimated numbers of people infected with TB in Africa are declining since the rollout of antiretroviral therapy a decade ago, TB is still the highest in the world. Early diagnosis and treatment of TB disease are essential to reducing morbidity and mortality. Transformative progress will never be possible with the current diagnostic tools as they rely on the detection of active TB which usually happen after disease has already been spread to others. Diagnostic technologies to accurately detect who will develop active TB are under development. However, their performance is not well reported. A better TB prediction test is needed to detect TB before clinical manifestation. The PreFIT investigators hypothesize that volunteers with a combination of positive Xpert HR result, high CRP, and/or low Hb levels will likely progress to active TB within 12 months. They also hypothesize that those with TB will have early high Hepcidin, Ferritin and Transferrin levels. The investigators plan to ask those found with TB at the local clinic if they accept to join the study. The participants, if they consent will then give information about people (contacts) who they stay with or meet frequently to also join the study. Contacts who have TB symptoms will be asked to cough sputum to be tested for co-prevalent TB disease. If they are found not to have TB disease, they will be asked to give blood: few drops from a finger prick and about 50mls from the vein on the arm to be stored and used for further tests. Follow-up and sampling of enrolled contacts without co-prevalent active TB will occur at six and 12 months (± 21 days before or after each time point, a six-week total window). Participants meeting presumptive TB or sputum expectorator definitions at six (M6) or 12 months (M12) of follow-up, or report with symptoms at any timepoint in-between, will undergo Xpert Ultra (or Xpert MTB/RIF if Ultra unavailable) and culture testing. All positive cultures will undergo whole genome sequencing (WGS) to track index case and co-prevalent or incident case transmission. Chest X-ray (CXR) will be done at M12 to potentially rule-out active disease missed by microbiological methods. Passive TB diagnoses (microbiological or empirical) throughout the follow-up period will be captured. To prevent diagnostic information bias, M0 and M6 test results for Xpert HR, CRP and haemoglobin will be kept concealed to the study nurse(s) and physician(s) who screen the cohort participants for active TB during follow-up. Similarly, laboratory technicians who test the stored samples for hepcidin, transferrin and ferritin will be blinded to whether the sample is from a participant who developed active TB during follow-up, or from a cohort participant who did not. The study will recruit 1515 trial participants each at Stellenbosch University in South Africa, 1515 at Centro de Investigação em Saúde de Manhiça in Mozambique and 1010 at Makerere University in Uganda. Participants will be between the ages of 12 and 60 years; pregnant women, minorities, economic and education disadvantaged, both HIV negative and positive will join the study. Contacts found to have co-prevalent active TB, potential pathologies on CXR, abnormal Hb and CRP levels will be referred to the local clinic for investigation per standard-of-care with a written summary of the relevant study results. All participant information will be treated in a strictly confidential manner and will be identified only by a code and not by any personal identifier. PreFIT's results will contribute to the development and uptake of accurate, cost-effective, scalable and field-friendly diagnostic tools, to facilitate scale-up of preventive treatment in sub-Saharan Africa and beyond. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04825327
Study type Observational [Patient Registry]
Source Amsterdam Institute for Global Health and Development
Contact
Status Active, not recruiting
Phase
Start date April 21, 2021
Completion date September 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2